Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 4
1993 2
1994 5
1995 3
1996 3
1997 4
1998 4
1999 5
2000 8
2001 8
2002 28
2003 34
2004 43
2005 78
2006 105
2007 125
2008 152
2009 176
2010 222
2011 240
2012 334
2013 319
2014 306
2015 266
2016 301
2017 284
2018 279
2019 252
2020 236
2021 238
2022 176
2023 180
2024 196
2025 255
2026 139

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,417 results

Results by year

Filters applied: . Clear all
Page 1
Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial.
Klausen MK, Jensen ME, Møller M, Le Dous N, Jensen AØ, Zeeman VA, Johannsen CF, Lee A, Thomsen GK, Macoveanu J, Fisher PM, Gillum MP, Jørgensen NR, Bergmann ML, Enghusen Poulsen H, Becker U, Holst JJ, Benveniste H, Volkow ND, Vollstädt-Klein S, Miskowiak KW, Ekstrøm CT, Knudsen GM, Vilsbøll T, Fink-Jensen A. Klausen MK, et al. JCI Insight. 2022 Oct 10;7(19):e159863. doi: 10.1172/jci.insight.159863. JCI Insight. 2022. PMID: 36066977 Free PMC article. Clinical Trial.
The glucagon-like peptide-1 (GLP-1) receptor agonist exenatide reduces alcohol consumption in rodents and nonhuman primates, but its efficacy in patients with AUD is unknown.MethodsIn a randomized, double-blinded, placebo-controlled clinical trial, treatment-seeking AUD pa …
The glucagon-like peptide-1 (GLP-1) receptor agonist exenatide reduces alcohol consumption in rodents and nonhuman primates, but its …
A Pilot Study of Exenatide Actions in Alzheimer's Disease.
Mullins RJ, Mustapic M, Chia CW, Carlson O, Gulyani S, Tran J, Li Y, Mattson MP, Resnick S, Egan JM, Greig NH, Kapogiannis D. Mullins RJ, et al. Curr Alzheimer Res. 2019;16(8):741-752. doi: 10.2174/1567205016666190913155950. Curr Alzheimer Res. 2019. PMID: 31518224 Free PMC article. Clinical Trial.
BACKGROUND: Strong preclinical evidence suggests that exenatide, a glucagon-like peptide-1 (GLP- 1) receptor agonist used for treating type 2 diabetes, is neuroprotective and disease-modifying in Alzheimer's Disease (AD). ...However, the analysis of secondary outcomes show …
BACKGROUND: Strong preclinical evidence suggests that exenatide, a glucagon-like peptide-1 (GLP- 1) receptor agonist used for treatin …
Exenatide.
Barnett AH. Barnett AH. Drugs Today (Barc). 2005 Sep;41(9):563-78. doi: 10.1358/dot.2005.41.9.893704. Drugs Today (Barc). 2005. PMID: 16341288 Review.
Exenatide is the first in a new class of compounds that exhibit activity similar to the naturally occurring hormone glucagon-like peptide-1 (GLP-1). ...Exenatide is generally well tolerated; nausea is the most commonly reported side effect, but it can be significant …
Exenatide is the first in a new class of compounds that exhibit activity similar to the naturally occurring hormone glucagon-like pep …
Exenatide.
Barnett A. Barnett A. Expert Opin Pharmacother. 2007 Oct;8(15):2593-608. doi: 10.1517/14656566.8.15.2593. Expert Opin Pharmacother. 2007. PMID: 17931093 Review.
Exenatide is the first in a new class of compounds, which possess similar activity to the naturally-occurring hormone glucagon-like peptide-1 (GLP-1). ...Exenatide is generally well tolerated; nausea is the most commonly reported side effect, but can be significantl …
Exenatide is the first in a new class of compounds, which possess similar activity to the naturally-occurring hormone glucagon-like p …
Pharmacokinetics of Exenatide in nonhuman primates following its administration in the form of sustained-release PT320 and Bydureon.
Li Y, Vaughan KL, Tweedie D, Jung J, Kim HK, Choi HI, Kim DS, Mattison JA, Greig NH. Li Y, et al. Sci Rep. 2019 Nov 20;9(1):17208. doi: 10.1038/s41598-019-53356-2. Sci Rep. 2019. PMID: 31748513 Free PMC article.
In contrast, Exenatide release from Bydureon exhibited a biphasic profile, with an initial plasma peak at 3 hr, followed by a rapid decline to a sub-therapeutic concentration, and a gradual elevation to provide a steady-state from day 35-49. Exenatide total e …
In contrast, Exenatide release from Bydureon exhibited a biphasic profile, with an initial plasma peak at 3 hr, followed by a …
[Medication of the month... Exenatide (Byetta) incretinomimetic in the treatment of type 2 diabetes after failure and as add-on therapy to oral agents].
Scheen AJ, Van Gaal LF. Scheen AJ, et al. Rev Med Liege. 2008 Mar;63(3):158-65. Rev Med Liege. 2008. PMID: 18561773 Free article. Review. French.
Exenatide (Byetta) is a synthetic derivative of exendin-4 and an agonist of receptors of glucagon-like peptide-1 (GLP-1). ...Exenatide may represent a valuable alternative to insulin therapy, especially in overweight or obese patients with type 2 diabetes and …
Exenatide (Byetta) is a synthetic derivative of exendin-4 and an agonist of receptors of glucagon-like peptide-1 (GLP-1). ... …
A double-blind, placebo-controlled trial of exenatide for the treatment of olanzapine-related weight gain in obese and overweight adults.
Patino LR, Strawn JR, Adler CM, Blom TJ, Welge JA, DelBello MP. Patino LR, et al. J Affect Disord. 2025 Aug 1;382:116-122. doi: 10.1016/j.jad.2025.04.046. Epub 2025 Apr 7. J Affect Disord. 2025. PMID: 40203970 Clinical Trial.
OBJECTIVE: To assess the safety and efficacy of exenatide in overweight or obese patients treated with olanzapine. METHODS: Adults with stable major mood or psychotic disorders were randomized to double-blind exenatide or placebo for 16 weeks. ...CONCLUSIONS: Exe …
OBJECTIVE: To assess the safety and efficacy of exenatide in overweight or obese patients treated with olanzapine. METHODS: Adults wi …
[Exenatide (Byetta)].
Duh D, Vandevijver A. Duh D, et al. J Pharm Belg. 2008 Mar;63(1):29-30. J Pharm Belg. 2008. PMID: 18479081 French. No abstract available.
[Bydureon: first once weekly GLP-1 receptor agonist (exenatide LAR)].
Scheen AJ. Scheen AJ. Rev Med Liege. 2014 Apr;69(4):214-9. Rev Med Liege. 2014. PMID: 24923102 Free article. French.
Bydureon is a new galenic formulation (long-acting release) of exenatide, the first agonist of Glucagon-Like Peptide-1 (GLP-1) receptors having been commercialized for the management of type 2 diabetes. The microsphere technology permits a prolonged absorption of …
Bydureon is a new galenic formulation (long-acting release) of exenatide, the first agonist of Glucagon-Like Peptide-1 (GLP-1) …
Exenatide.
Keating GM. Keating GM. Drugs. 2005;65(12):1681-92; discussion 1693-5. doi: 10.2165/00003495-200565120-00008. Drugs. 2005. PMID: 16060703
Relative to placebo, reductions from baseline in bodyweight were significantly greater with twice-daily exenatide 5microg (in two studies) or 10microg (in all three studies). Post hoc completer analyses revealed that the beneficial effects of exenatide on HbA(1c) an …
Relative to placebo, reductions from baseline in bodyweight were significantly greater with twice-daily exenatide 5microg (in two stu …
4,417 results